Captain CAR

Exploring the ocean of genetically engineered immune cells and Chimeric Antigen Receptors

[Captain CAR @CaptainTCell]

#FDA update on #ilixadencel, an autologous #dendritic cell based therapy for gastrointestinal stromal #tumours @Immunicum

[Penn Medicine @PennMedicine]

Today is a major milestone in cancer treatment history. It's been 10 years since Emily Whitehead became the first pediatric patient in the world to receive #CARTcell therapy, developed by Penn & in collaboration w/ @ChildrensPhila. Catch Emily on the @TODAYshow tomorrow morning!

[Captain CAR @CaptainTCell]

The first ever #CART cell symposium on the 19th of May. Interesting program with great speakers. Hosted by @DTUtweet

[Captain CAR @CaptainTCell]

The ZUMA-12 Phase II study with #Yescarta show 78% CR as first-line treatment. Benifits of first line show increased T cell fitness (increased CCR7+CD45RA) compared to products from heavily treated patients (ZUMA-1). @KitePharma https://t.co/QqBMg5yder

[Captain CAR @CaptainTCell]

Detection of anti-CD19 #CAR #Tcells using the anti-mouse F(ab')2 fragment specific antibody is superior to protein L and CD19 protein and correlates good with qPCR. Study in @MDPIOpenAccess @Cells_MDPI

[Evan Weber @EvanWeberPhD]

Game-changing work from @yarmo111 and the Maris lab @CHOP_Research showing that specific peptide/HLA combos are enriched in neuroblastoma and that they can be targeted with conventional scFv CARs!

Are peptide-centric CARs the future of CAR-T therapy?

https://t.co/nZQDXWbzQH

[Captain CAR @CaptainTCell]

#CART #Costimulation is essential for #TCell activation, persistance and anti-tumor reactivity. #41BB and mutated #CD28 improves persistance of a 3rd gen. #CAR. Published in @bmj_company (FREE)
https://t.co/bYcVV0aCGy

[Captain CAR @CaptainTCell]

This 2019 review fron Xu et al. highlights mechanisms of #relapse in #CD19 #CAR #TCell #Therapies. Interestingly, they highlight up to 60% relapse with the majority being CD19+. Possibly driven by poor T Cell fitness @FrontImmunol https://t.co/PSOuoCOE5I

[NatureRevClinOncol @NatRevClinOncol]

Another Review now live online. In this article, Robert Gatenby & Joel Brown discuss the concept of 'Integrating evolutionary dynamics into cancer therapy': https://t.co/lRVu2gcmgu

[Emily Whitehead Foundation @EWhiteheadFdn]

Today, Emily is 8 years cancer free!

#WeBelieve #ActivateTheCure

[Waggoner Lab @LabWaggoner]

An HIV vaccine that elicits both antibodies and cellular immune responses confers long-lasting protection against viral challenge in nonhuman primates. https://t.co/lRPtqsaFwr

[Luis Álvarez-Vallina @Alvarez_Vallina]

Trimerbody based therapies for COVID-19: targeting SARS-CoV-2 viral entry mechanism by next-gen trimeric Spikebodies

[McHeyzer-Williams @mmw_lmw]

Visualization of #T_Cell_Migration in the #Spleen | Reveals a Network of Perivascular Pathways that Guide #Entry_into_T_Zones | Tal Arnon @UniofOxford @ImmunityCP https://t.co/C3otR9ZZL8

[Roger Olofsson Bagge @OlofssonBagge]

A proud day in research! Designing a clinical trial (#SCANDIUM ) where tumor biopsies now finally has helped us to profile driver events in metastatic #uvealmelanoma Proud 2nd senior author ⁦@NatureComms⁩ ! Collaboration with ⁦@JNilsson_lab⁩ https://t.co/5yZPbUV04C

[Wael Awad @WaelAwadMoh]

https://t.co/cuO3deeytB

[Frontiers - Immunology @FrontImmunol]

New Research: Distinct Dysfunctional States of Circulating Innate-Like T Cells in Metabolic Disease: The immune system plays a significant role in controlling systemic metabolism. Innate-like T (ILT) cells in particular, such as… https://t.co/WUbZqC8PXP #immunology

[FlyBase @FlyBaseDotOrg]

FlyBase has partnered with pAbmAbs https://t.co/giH8DRbqUJ, a nonprofit resource to help researchers identify antibodies that work well or do not work well for their particular application by cataloguing both positive and negative community-submitted antibody reviews. @pAbmAbs

[Annals of Oncology @Annals_Oncology]

Letter to the Editor in Annals of Oncology reporting the successful treatment of a patient with cancer and severe pulmonary manifestations of #COVID19 with Tocilizumab, anti-IL6 receptor moAb used for treating CRS seen with CAR-Ts @MichotJM @GustaveRoussy https://t.co/mrNJ3T1DEX

[Kamar Johnson @johnson_kamar]

Haha I didn’t know this was a thing @biotechne @CGTCatapult @DrQasimRafiq @CaptainTCell

[Prof. Akiko Iwasaki @VirusesImmunity]

Let's dispel the notion that "novel coronavirus is just like the flu". Sharing this striking comparison of #Flu, #COVID19, #SARS and #MERS made by @BioRender.

#COVID19 is 30x more deadly and almost 2x more contagious than the flu. We have no existing immunity to COVID19.